BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stolley DL, Crouch AC, Özkan A, Seeley EH, Whitley EM, Rylander MN, Cressman ENK. Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies. Pharmaceutics 2020;12:E1243. [PMID: 33419304 DOI: 10.3390/pharmaceutics12121243] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Renga G, Nunzi E, Pariano M, Puccetti M, Bellet MM, Pieraccini G, D'Onofrio F, Santarelli I, Stincardini C, Aversa F, Riuzzi F, Antognelli C, Gargaro M, Bereshchenko O, Ricci M, Giovagnoli S, Romani L, Costantini C. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite. J Immunother Cancer 2022;10:e003725. [PMID: 35236743 DOI: 10.1136/jitc-2021-003725] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chen G, Chang M, Chang S, Ho Y, Chang H. Cytotoxicity and Apoptosis Induction of 6,7-Dehydroroyleanone from Taiwania cryptomerioides Bark Essential Oil in Hepatocellular Carcinoma Cells. Pharmaceutics 2022;14:351. [DOI: 10.3390/pharmaceutics14020351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Özkan A, Stolley DL, Cressman ENK, McMillin M, DeMorrow S, Yankeelov TE, Rylander MN. Tumor Microenvironment Alters Chemoresistance of Hepatocellular Carcinoma Through CYP3A4 Metabolic Activity. Front Oncol 2021;11:662135. [PMID: 34262860 DOI: 10.3389/fonc.2021.662135] [Reference Citation Analysis]
4 Gu YF, Kong LT. Inhibiting p21-activated kinase (PAK7) enhances radiosensitivity in hepatocellular carcinoma. Hum Exp Toxicol 2021;:9603271211027948. [PMID: 34165002 DOI: 10.1177/09603271211027948] [Reference Citation Analysis]